AMHR2

Across TCGA pan-cancer cohorts, AMHR2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of AMHR2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where AMHR2 RNA is repressed in tumor relative to normal tissue. In most cancer types AMHR2 is over-expressed in tumor, although a few such as LIHC and LUSC show the opposite, repressed pattern.

LIHC, LUSC, and BLCA are the cancer types where AMHR2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AMHR2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	III,IV	−0.611	<.001	8	view →
LUSC	Male	III,IV	−0.320	<.001	8	view →
BLCA	All	IV	−0.147	<.001	8	view →
COAD	Female	All	−0.105	<.001	6	view →
CHOL	All	All	−0.316	<.001	5	view →
UCEC	All	All	−0.708	.039	2	view →
LUAD	Male	II,III,IV	−0.174	.013	2	view →
PRAD	All	All	+0.127	<.001	2	view →
READ	All	All	−0.100	.020	2	view →
KIRC	Male	All	+0.018	.018	2	view →
STAD	Male	II,III,IV	−0.092	.045	1	view →
KIRP	All	All	+0.076	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

AMHR2–LIHC

Open the LIHC breakdown →